This report was first published by Endpoints News. To see the original version, click here
Pfizer said Tuesday that the monthly injection that was one of the cornerstones of its $10 billion buyout of Metsera allowed obesity patients to lose up to 10.5% of their weight, on a placebo-adjusted basis, after just over six months.
The data are from the Phase 2b VESPER-3 study, testing weekly doses of PF-08653944 (also known as MET-097i) titrated up to 1.2 mg for 12 weeks, and then monthly doses of 4.8 mg for another 16 weeks. For the treatment policy estimand, which uses all available weight measurements regardless of treatment adherence, placebo-adjusted weight loss was 8.4% for Arm 1 and 10.5% for Arm 3.
您已阅读36%（707字），剩余64%（1268字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。